Organogenesis Holdings Inc. provided earnings guidance for the year ending December 31, 2022. For the year, the company expected net revenue of between $485 million and $515 million, representing an increase of approximately 4% to 10% year-over-year as compared to net revenue of $468.1 million for the year ended December 31, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.47 USD | -3.89% | -6.44% | -39.61% |
May. 13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
May. 10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.61% | 327M | |
+34.01% | 51.07B | |
+34.78% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022